FDB agrees to manufacture Argenx’s antibody therapy efgartigimod

By NS Healthcare Staff Writer

28 Oct 22

Under the agreement, FDB will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød,…

PharmaceuticalsContract Manufacturing

AstraZeneca, Gatehouse Bio extend partnership to develop RNA therapeutics for heart failure

By NS Healthcare Staff Writer

09 Sep 22

The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…

PharmaceuticalsPartnerships and Licensing Agreements

Moderna to supply additional doses of bivalent Covid-19 booster vaccine to US

By NS Healthcare Staff Writer

01 Aug 22

Under the new agreement with the US government, the biotechnology company will receive up to $1.74bn for 66…

PharmaceuticalsPartnerships and Licensing Agreements

GenScript, ACT Therapeutics partner to develop new CAR-T Cell therapies

By NS Healthcare Staff Writer

13 Jul 22

GenScript ProBio will support ACT therapeutics’ CAR-T Platform (ACT platform), an immune cell-based cell and gene therapy technology…

PharmaceuticalsPartnerships and Licensing Agreements

Roche licenses Ionis’ investigational therapy for rare kidney disease

By NS Healthcare Staff Writer

12 Jul 22

Ionis will receive $55m from Roche, in exchange for licensing IONIS-FB-LRx and achieving a development milestone in the…

PharmaceuticalsPartnerships and Licensing Agreements

Akebia terminates license deal with Otsuka to retain vadadustat rights

By NS Healthcare Staff Writer

04 Jul 22

The company is entitled to receive a settlement fee of $55m and will assume responsibility for the marketing…

PharmaceuticalsPartnerships and Licensing Agreements

ViiV Healthcare teams up with MPP to license patents related to HIV drug cabotegravir

By NS Healthcare Staff Writer

30 May 22

ViiV Healthcare and MPP are actively negotiating on terms of a voluntary licensing agreement, which would help widen…

PharmaceuticalsPartnerships and Licensing Agreements

Exscientia, Oxford TDI partner for Xcellomics drug discovery programme

By NS Healthcare Staff Writer

11 Mar 22

Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…

PharmaceuticalsDrug discovery

AstraZeneca, Neurimmune to jointly develop cardiomyopathy drug NI006

By NS Healthcare Staff Writer

02 Mar 22

Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…

PharmaceuticalsPartnerships and Licensing Agreements

ImmunoGen licenses novel camptothecin ADC platform to Lilly for up to $1.7bn

By NS Healthcare Staff Writer

16 Feb 22

ImmunoGen will receive $13m in upfront payment for initial targets and is eligible to receive an additional $32.5m…

PharmaceuticalsPartnerships and Licensing Agreements